Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
The complement system provides critical immunoprotective and immunoregulatory functions but uncontrolled complement activation can lead to severe pathology. In the rare hemolytic disease paroxysmal nocturnal hemoglobinuria (PNH), somatic mutations result in a deficiency of glycosylphosphatidylinositol-linked surface proteins, including the terminal complement inhibitor CD59, on hematopoietic stem cells. In a dysfunctional bone marrow background, these mutated progenitor blood cells expand and populate the periphery. Deficiency of CD59 on PNH red blood cells results in chronic complement-mediated intravascular hemolysis, a process central to the morbidity and mortality of PNH. A recently developed, humanized monoclonal antibody directed against complement component C5, eculizumab (Soliris; Alexion Pharmaceuticals Inc., Cheshire, CT, USA), blocks the proinflammatory and cytolytic effects of terminal complement activation. The recent approval of eculizumab as a first-in-class complement inhibitor for the treatment of PNH validates the concept of complement inhibition as an effective therapy and provides rationale for investigation of other indications in which complement plays a role.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Eculizumab exemplifies a more extreme case. It binds human complement component C5 with high affinity but does not cross-react with rodent C5. Conventional rodent PK and pharmacology studies are therefore essentially uninformative regarding target engagement.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [53]
Citations
Cites
1 retracted
The structure of complement C3b provides insights into complement activation and regulation
Ajees, A. A., Gunasekaran, K., Volanakis, J. E., Narayana, S. V. L., Kotwal, G. J., & Murthy, H. M. K. (2006) · Nature · doi:10.1038/nature05258 · Cited by 70
RetractedHematology: Basic Principles and Practice
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-3-238_2 · Cited by 1,857
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Rother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Walport, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104123441506 · Cited by 1,481
ENDOGENOUS NITRIC OXIDE INHIBITS HUMAN PLATELET ADHESION TO VASCULAR ENDOTHELIUM
Radomski, M. W., Palmer, R. M. J., & Moncada, S. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91481-4 · Cited by 1,437
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Young, N. S., Schubert, J., Brodsky, R. A., Socié, G., Muus, P., Röth, A., Szer, J., Elebute, M. O., Nakamura, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061648 · Cited by 1,303
Radomski, M. W., Palmer, R. M. J., & Moncada, S. (1987) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1987.tb11367.x · Cited by 1,164
Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., Takahashi, M., Kitani, T., & Kinoshita, T. (1993) · Cell · doi:10.1016/0092-8674(93)90250-t · Cited by 1,029
Generation of C5a in the absence of C3: a new complement activation pathway
Huber-Lang, M., Sarma, J. V., Zetoune, F. S., Rittirsch, D., Neff, T. A., McGuire, S. R., Lambris, J. D., Warner, R. L., Flierl, M. A., Hoesel, L. M., et al. (2006) · Nature Medicine · doi:10.1038/nm1419 · Cited by 975
Research works printed but not linked: 4
- Male, D., Brostoff, J., Roth, D. & Roitt, I. Immunology (Mosby-Elsevier, Philadelphia, 2006).
- Jain, R.I., Moreland, L.W., Caldwell, J.R., Rollins, S.A. & Mojcik, C.F. A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 42, S77 (1999).
- Tesser, J. et al. Safety and efficacy of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 44, S274 (2001).
- Rotoli, B. & Luzzatto, L. Paroxysmal nocturnal hemoglobinuria. Semin. Hematol. 26, 201–207 (1989).
Cited by
Items 201–300 of 780
Neonatal Fc Receptor–Targeted Therapies in Neurology
Nelke, C., Spatola, M., Schroeter, C. B., Wiendl, H., & Lünemann, J. D. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01175-7 · Cited by 50
“However, the terminal half-life of ~ 11 days requires dosing every two weeks to maintain treatment efficacy [90].”
BackgroundEculizumab hepatotoxicity in pediatric aHUS
Hayes, W. N., Tschumi, S., Ling, S. C., Feber, J., Kirschfink, M., & Licht, C. P. B. (2014) · Pediatric Nephrology · doi:10.1007/s00467-014-2990-5 · Cited by 49
“Eculizumab is a humanized monoclonal anti-C5 antibody [26] that has been used for over a decade in patients with paroxysmal nocturnal hemoglobinuria (PNH) [1, 3] and aHUS [8] in patients of all age groups.”
BackgroundAtypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management
Sridharan, M. R., Go, R. S., & Willrich, M. A. V. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.07.006 · Cited by 52
“AC CE PT ED M AN US CR IP T pathway through simultaneous blockade of the generation of the potent pro-thrombotic and pro-inflammatory molecule, C5a, and the formation of membrane attack complex initiator, C5b (Thomas et al., 1996; Rother et al., 2007).”
BackgroundBroadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease
Ozen, A., Kasap, N., Vujkovic-Cvijin, I., Apps, R., Cheung, F., Karakoç-Aydıner, E., Akkelle, B. Ş., Sarı, S., Tutar, E., Özçay, F., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00830-z · Cited by 50
C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications
Notaro, R., & Sica, M. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.05.014 · Cited by 51
A double edged-sword - The Complement System during SARS-CoV-2 infection
Santiesteban-Lores, L. E., Amamura, T. A., da Silva, T. F., Midon, L. M., Carneiro, M. C., Isaac, L., & Bavia, L. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119245 · Cited by 50
“In fact, patients who were on anti-Complement therapy to treat PNH at the time they became infected with SARS-CoV-2 had relatively milder symptoms [73,74].”
BackgroundInfluentialMastellos, D. C., Ricklin, D., Yancopoulou, D., Risitano, A. M., & Lambris, J. D. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.953926 · Cited by 53
“Complement activation via all pathways may lead to the convertase-mediated cleavage of C5, which in turn results in the generation of its bioactive fragments, C5b and C5a [68,64].”
BackgroundInfluentialComplement 7 Is Up-Regulated in Human Early Diabetic Kidney Disease
Sircar, M., Rosales, I. A., Selig, M. K., Xu, D., Zsengellér, Z. K., Stillman, I. E., Libermann, T. A., Karumanchi, S. A., & Thadhani, R. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.06.018 · Cited by 47
Guía diagnóstica y terapéutica de las microangiopatías trombóticas del Grupo Español de Aféresis
Contreras, E., de la Rubia, J., del Río-Garma, J., Díaz‐Ricart, M., Gala, J. M. G., & Lozano, M. (2014) · Medicina Clínica · doi:10.1016/j.medcli.2014.09.013 · Cited by 46
Role of the Skin Biopsy in the Diagnosis of Atypical Hemolytic Uremic Syndrome
MAGRO, C. M. J., Momtahen, S., Mulvey, J. J., Yassin, A. H., Kaplan, R. B., & Laurence, J. C. (2015) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000234 · Cited by 49
“Our immunohistochemical protocol for the assessment of C3d, C4d, and MAC/C5b-9 has been previously described and used (Vision Bio Systems) for C3d and C4d and (Leica Microsystems) for MAC/C5b-9.(11,12) RESULTS”
MethodInfluentialLatuszek, A., Liu, Y., Olsen, O., Foster, R., Cao, M., Lovric, I., Yuan, M., Liu, N., Chen, H., Zhang, Q., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231892 · Cited by 46
“In-house eculizumab, on the other hand, did not bind monkey C5 under similar conditions, consistent with published results [13, 14] .”
Nakayama, H., Usuki, K., Echizen, H., Ogawa, R., & Orii, T. (2016) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00703 · Cited by 45
Wagner, E., Colas, O., Chenu, S., Goyon, A., Murisier, A., Cianférani, S., François, Y., Fekete, S., Guillarme, D., D’Atri, V., et al. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113166 · Cited by 45
Risitano, A. M., Marando, L., Seneca, E., & Rotoli, B. (2008) · Blood · doi:10.1182/blood-2008-04-151613 · Cited by 45
Mannes, M., Pechtl, V., Häfner, S., Dopler, A., Eriksson, O., Manivel, V. A., Wohlgemuth, L., Messerer, D. A. C., Schrezenmeier, H., Ekdahl, K. N., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010817 · Cited by 44
“8,9 Several other disease entities exhibit a substantial complement activation signature, which leads to thrombosis despite application of established antithrombotic drugs (reviewed in 10,11 ).”
BackgroundPauly, D., Nagel, B. M., Reinders, J., Killian, T., Wulf, M., Ackermann, S., Ehrenstein, B. P., Zipfel, P. F., Skerka, C., & Weber, B. H. F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096371 · Cited by 50
“8 nM) [52,53].”
Complement‐targeted therapeutics: Are we there yet, or just getting started?
Ricklin, D. (2024) · European Journal of Immunology · doi:10.1002/eji.202350816 · Cited by 54
“Most currently targeted indications have well-defined complement-driven mechanisms, and the selection of PNH as the quintessential complementopathy was instrumental in the breakthrough of complement therapeutics [14].”
InfluentialAdvances in immunosuppression for renal transplantation
Dürrbach, A., François, H., Beaudreuil, S., Jacquet, A., & Charpentier, B. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.233 · Cited by 47
“The drug acts against complement C5 and was developed to treat paroxysmal nocturnal hemoglobinuria, which is related to the deficiency of glycosylphosphatidylinositol-linked surface proteins, including the terminal complement inhibitor CD59”
BackgroundThe complement system: an evolution in progress
Ghebrehiwet, B. (2016) · F1000Research · doi:10.12688/f1000research.10065.1 · Cited by 43
Complement C5 Contributes to Brain Injury After Subarachnoid Hemorrhage
van Dijk, B. J., Meijers, J. C. M., Kloek, A. T., Knaup, V. L., Rinkel, G. J. E., Morgan, B. P., van der Kamp, M. J., Osuka, K., Aronica, E., Ruigrok, Y. M., et al. (2019) · Translational Stroke Research · doi:10.1007/s12975-019-00757-0 · Cited by 44
Monoclonal Antibody-Based Therapies for Myasthenia Gravis
Alabbad, S., AlGaeed, M., Sikorski, P. M., & Kaminski, H. J. (2020) · BioDrugs · doi:10.1007/s40259-020-00443-w · Cited by 44
Eculizumab versus rituximab in generalised myasthenia gravis
Nelke, C., Schroeter, C. B., Stascheit, F., Pawlitzki, M., Regner-Nelke, L., Huntemann, N., Arat, E., Öztürk, M., Melzer, N., Mergenthaler, P., et al. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328665 · Cited by 48
An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA
Thomas, K. A., Valenzuela, N. M., Gjertson, D., Mulder, A., Fishbein, M. C., Parry, G. C., Panicker, S., & Reed, E. F. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13273 · Cited by 42
“Current therapies targeted at minimizing complement-mediated damage to the graft aim to block complement protein activation (27), specifically monoclonals directed against C5, which inhibit C5a production and MAC formation (30).”
BackgroundOrnithodoros moubata Complement Inhibitor Is an Equally Effective C5 Inhibitor in Pigs and Humans
Barratt‐Due, A., Thorgersen, E. B., Lindstad, J. K., Pharo, A. M., Lissina, O., Lambris, J. D., Nunn, M. A., & Mollnes, T. E. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101000 · Cited by 42
“C5 inhibition by OmCI thus has vast anti-inflammatory potential, without affecting beneficial immunoprotective and immunoregulatory functions of upstream C activity (20).”
BackgroundThe pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab
Kelly, R. J. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3334 · Cited by 42
“Eculizumab was initially evaluated in the treatment of patients with rheumatoid arthritis and systemic lupus erythematosis.(51,52) These early clinical studies provided information on the frequency of dosing as well as the doses required to provide complement blockade.”
Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future
Risitano, A. M., & Marotta, S. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.05.001 · Cited by 45
“The history of complement inhibition in hemolytic anemias Eculizumab (Soliris®, Alexion) [5] is the first complement inhibitor approved for clinical use in humans, initially for PNH and subsequently for aHUS.”
BackgroundInfluentialComplement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery
Mastellos, D. C., Reis, E. S., Ricklin, D., Smith, R. J., & Lambris, J. D. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.03.003 · Cited by 42
“From a different standpoint, therapeutic targeting of the terminal pathway, either by C5 blockade or inhibition of C5a-triggered activation of effector responses, represents a viable approach for containing clinical manifestations that are largely driven by terminal pathway effectors (such as C5a and the MAC).”
BackgroundInfluentialComplement in Kidney Transplantation
Cernoch, M., & Viklický, O. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00066 · Cited by 47
“The composition FiGURe 1 | The simplified overview of main complement activation pathways (MBL, mannose-binding lectin; MAC, membrane attack complex); three main activation pathways are recognized in the complement system, leading to anaphylatoxin release and MAC formation: classical and lectin pathways are reliant on…”
BackgroundInfluentialcorrespondence: Pregnancy in PNH: another eculizumab baby
Marasca, R., Coluccio, V., Santachiara, R., Leonardi, G., Torelli, G., Notaro, R., & Luzzatto, L. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08258.x · Cited by 43
“We were also aware that the Fc portion of eculizumab is a hybrid of IgG4 and IgG2 (Rother et al, 2007), and that the latter is the less prone to cross the placenta (Simister, 2003).”
BackgroundFrom discovery to approval: A brief history of the compstatin family of complement C3 inhibitors
Mastellos, D. C., Ricklin, D., Sfyroera, G., & Sahu, A. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108785 · Cited by 42
Treatment of Enterohemorrhagic Escherichia coli–Induced Hemolytic Uremic Syndrome (eHUS)
Riedl, M., Rosales, A., Orth‐Höller, D., & Würzner, R. (2014) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0034-1375298 · Cited by 42
Monoclonal Antibody Therapy and Renal Transplantation: Focus on Adverse Effects
Zaza, G., Tomei, P., Granata, S., Boschiero, L., & Lupo, A. (2014) · Toxins · doi:10.3390/toxins6030869 · Cited by 41
“complex (C5-9) [125].”
Lau, C., Gunnarsen, K. S., Høydahl, L. S., Andersen, J. T., Berntzen, G., Pharo, A. M., Lindstad, J. K., Ludviksen, J. K., Brekke, O., Barratt‐Due, A., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301653 · Cited by 46
“complement factor 5 (C5) Ab eculizumab (Soliris), however, effector functions are not desired and have been minimized by the use of a hybrid Fc portion, which consists of sequences from human IgG2 and IgG4 to minimize both FcgR binding (IgG2 portion) and complement activation (IgG4 portion) (14, 15).”
BackgroundSeow, V., Lim, J., Cotterell, A. J., Yau, M., Xu, W., Lohman, R., Kok, W. M., Stoermer, M. J., Sweet, M. J., Reid, R. C., et al. (2016) · Scientific Reports · doi:10.1038/srep24575 · Cited by 40
Frazer‐Abel, A. A., Sepiashvili, L., Mbughuni, M. M., & Willrich, M. A. V. (2016) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.06.001 · Cited by 48
Höchsmann, B., Leichtle, R., von Zabern, I., Kaiser, S., Flegel, W. A., & Schrezenmeier, H. (2011) · Vox Sanguinis · doi:10.1111/j.1423-0410.2011.01530.x · Cited by 46
With complements: C3 inhibition in the clinic
Kolev, M. V., Barbour, T., Baver, S. B., Francois, C. G., & Deschatelets, P. (2022) · Immunological Reviews · doi:10.1111/imr.13138 · Cited by 43
Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future
Crisafulli, S., Boccanegra, B., Carollo, M., Bottani, E., Mantuano, P., Trifirò, G., & Luca, A. D. (2024) · CNS Drugs · doi:10.1007/s40263-023-01059-8 · Cited by 49
“1, was identified and subsequently humanized to reduce potential immunogenicity [42, 43].”
Bride and groom in systemic inflammation – The bells ring for complement and Toll in cooperation
Barratt‐Due, A., Pischke, S. E., Brekke, O., Thorgersen, E. B., Nielsen, E. W., Espevik, T., Huber-Lang, M. S., & Mollnes, T. E. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.07.019 · Cited by 42
Pischke, S. E., Gustavsen, A., Orrem, H. L., Egge, K. H., Courivaud, F., Fontenelle, H., Despont, A., Bongoni, A. K., Rieben, R., Tønnessen, T., et al. (2017) · Basic Research in Cardiology · doi:10.1007/s00395-017-0610-9 · Cited by 40
“6 lM eculizumab because of the double-binding property of the antibody eculizumab in contrast to the single-chain variant pexelizumab [38].”
BackgroundEculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes
Sica, M., Rondelli, T., Ricci, P., Angioletti, M. D., Risitano, A. M., & Notaro, R. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0496-x · Cited by 40
“The blockade of terminal complement pathway by eculizumab [11], a monoclonal antibody (moAb) against complement component 5 (C5), abrogates intravascular hemolysis with the consequent normalization of lactate dehydrogenase (LDH) levels in almost all patients suffering from PNH.”
BackgroundPolyclonal and Monoclonal Antibodies in Clinic
Wootla, B., Đenić, A., & Rodriguez, M. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-586-6_5 · Cited by 48
Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis
Monteleone, J. P. R., Gao, X., Kleijn, H. J., Bellanti, F., & Pelto, R. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.696385 · Cited by 39
“This supports terminal complement inhibition as the mechanism by which eculizumab exerts its therapeutic effects with rapid onset in patients with gMG (2, 20).”
BackgroundInfluentialManaging a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab
Danilov, A. V., Brodsky, R. A., Craigo, S., Smith, H. P., & Miller, K. B. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.10.025 · Cited by 40
Paroxysmal Nocturnal Hemoglobinuria: Stem Cells and Clonality
Brodsky, R. A. (2008) · Hematology · doi:10.1182/asheducation-2008.1.111 · Cited by 39
“The median survival for PNH patients is 10 to 15 years after diagnosis; however, the recent advent of eculizumab, a novel monoclonal antibody that decreases hemolysis and thrombosis in PNH, may alter the natural history.(1,2) Prior to eculizumab, thrombosis was the leading cause of death, but additional patients died…”
BackgroundExpanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
Mastellos, D. C., Reis, E. S., Yancopoulou, D., Risitano, A. M., & Lambris, J. D. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.02.002 · Cited by 41
“This AP-amplified opsonic turnover triggers C5 convertase activity that leads to MAC assembly on target cells.”
InfluentialDynamic control of the complement system by modulated expression of regulatory proteins
Thurman, J. M., & Renner, B. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.173 · Cited by 41
“Numerous agents have been developed to prevent complement-mediated injury,(75) and one of these agents, eculizumab, has recently entered clinical use.(76) Tissue-targeted complement inhibitors may be able to restore control of the complement system specifically to the tissue sites where this control”
BackgroundTherapeutic Monoclonal Antibodies: Past, Present, and Future
Strohl, W. R. (2009) · Wiley eBooks · doi:10.1002/9780470485408.ch1 · Cited by 49
“In part because Orthoclone OKT3w caused these significant adverse events, in part because the biotechnology field was rapidly changing with new technologies being proposed and developed, in part because the discovery and development timelines for drugs are so long (averaging approximately 8 to 10 years from discovery…”
BackgroundInfluentialSchrezenmeier, H., Bettelheim, P., Panse, J., Schubert, J. E. A., Höchsmann, B., Röth, A., & Nebe, T. (2011) · Journal of Laboratory Medicine · doi:10.1515/jlm.2011.060 · Cited by 38
Targeting therapy to the neuromuscular junction: Proof of concept
Kusner, L. L., Satija, N., Cheng, G., & Kaminski, H. J. (2013) · Muscle & Nerve · doi:10.1002/mus.24057 · Cited by 38
“the only complement inhibitor in clinical use, which is estimated to be in the range of 1–290 nM.(32,33) We did not completely ablate the effects of EAMG, but only a single dose was evaluated.”
BackgroundLong-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial
Kanakura, Y., Ohyashiki, K., Shichishima, T., Okamoto, S., Ando, K., Ninomiya, H., Kawaguchi, T., Nakao, S., Nakakuma, H., Nishimura, J., et al. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1404-y · Cited by 41
“Eculizumab, a humanized monoclonal antibody, specifically targets the terminal complement protein C5, thereby inhibiting chronic uncontrolled complement activity and complement-mediated hemolysis [27].”
BackgroundWhat’s new in neuromyelitis optica? A short review for the clinical neurologist
Whittam, D. H., Wilson, M., Hamid, S. H. M., Keir, G., Bhojak, M., & Jacob, A. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8445-8 · Cited by 43
“Eculizumab is a humanized monoclonal IgG antibody that neutralises the complement protein C5, preventing formation of the C5b-9 membrane attack complex [107].”
BackgroundChamberlain, J. L., Huda, S., Whittam, D. H., Matiello, M., Morgan, B. P., & Jacob, A. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09498-4 · Cited by 37
Bauer, M. W., Weyland, A., Marx, G., Bloos, F., Weber, S., Weiler, N., Kluge, S., Diers, A., Simon, T. P., Lautenschläger, I., et al. (2021) · Critical Care Explorations · doi:10.1097/cce.0000000000000577 · Cited by 38
“C5b and subsequent membrane attack complex (MAC) formation is important for bacterial host defense and its inhibition by approved C5 inhibitors such as eculizumab increases susceptibility to infections (7), especially with encapsulated bacteria such as Neisseria (8, 9).”
BackgroundComplement as a Therapeutic Target in Systemic Autoimmune Diseases
Galindo-Izquierdo, M., & Pablos, J. L. (2021) · Cells · doi:10.3390/cells10010148 · Cited by 40
Muduma, G., Odeyemi, I., Smith-Palmer, J., & Pollock, R. F. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0292-y · Cited by 35
“monoclonal antibody directed against the terminal C5 complement protein, thereby preventing the initiation of the terminal complement cascade normally started by the cleavage of C5 into C5a and C5b [26].”
BackgroundConsistent improvement with eculizumab across muscle groups in myasthenia gravis
Mantegazza, R., O’Brien, F., Yountz, M., Howard, J. F., & for the REGAIN study group (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51121 · Cited by 37
Kulasekararaj, A. G., Hill, A., Langemeijer, S. M. C., Wells, R. A., Fernández, F. A. G., Gayà, A., Gutierrez, E. O., Piatek, C. I., Mitchell, L. D., Usuki, K., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13564 · Cited by 40
Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species
Zelek, W. M., & Morgan, B. P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.612402 · Cited by 36
Weinstock, C., Möhle, R., Dorn, C., Weisel, K. C., Höchsmann, B., Schrezenmeier, H., & Kanz, L. (2014) · Transfusion · doi:10.1111/trf.12882 · Cited by 36
“It completely blocks terminal complement for at least 1 week.(6-8,13) Like in the induction period of PNH and aHUS treatment we recommend to repeat eculizumab weekly as long as a substantial proportion of incompatible RBCs is still present and there is evidence of ongoing hemolysis.”
BackgroundTreatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab
Röth, A., & Dührsen, U. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01701.x · Cited by 35
“Germline human framework acceptor sequences were used to minimize immunogenicity and the human IgG2 ⁄ 4 heavy chain constant regions added to eliminate the ability to bind Fc receptors and activate complement (24, 26).”
BackgroundColley, C. S., Popovic, B., Sridharan, S., Debreczeni, J. E., Hargeaves, D., Fung, M. S. C., An, L., Edwards, B. M., Arnold, J., England, E., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1384892 · Cited by 36
Berger, N., Alayi, T. D., Resuello, R. R. G., Tuplano, J. V., Reis, E. S., & Lambris, J. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00560 · Cited by 35
Complement Involvement in Neovascular Ocular Diseases
Yanai, R., Thanos, A., & Connor, K. M. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0106-3_10 · Cited by 38
Chiba, S. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_2619 · Cited by 34
Complement inhibition as potential new therapy for antibody-mediated rejection
Eskandary, F. A., Wahrmann, M., Mühlbacher, J., & Böhmig, G. A. (2015) · Transplant International · doi:10.1111/tri.12706 · Cited by 37
“To avoid unwanted proinflammatory effector functions, mediated by Fc receptor binding or complement activation, the constant heavy chains and hinge region of the human IgG subclasses two and four were fused together [17,40].”
BackgroundInfluentialBlom, A. M., Österborg, A., Mollnes, T. E., & Okrój, M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.02.029 · Cited by 33
“Proteolysis takes place during the initiation of the alternative complement pathway (cleavage of C3 and factor B) and classical/lectin pathway (C2 and C4), during generation of C3a and C3b by C3 convertases, during inactivation of C3b and C4b opsonins by factor I (FI) (Nilsson et al., 2011), and finally at the transit…”
Im, S. J., Yang, S. I., Yang, S. H., Choi, D. H., Choi, S. Y., Kim, H. S., Jang, D. S., Jin, K. S., Chung, Y.-K., Kim, S., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024574 · Cited by 35
“utilization of IgG4 Fc [7] or hybrid IgG2/IgG4 Fc [10,11], but these could form monomeric molecules and/or hinder the bioactivity of Fc-fused molecules due to their less flexible hinge.”
BackgroundThe impact of eculizumab on routine complement assays
Willrich, M. A. V., Andreguetto, B. D., Sridharan, M. R., Fervenza, F. C., Tostrud, L. J., Ladwig, P. M., Rivard, A. L., Hetrick, M., Olson, R. N., Bryant, S. C., et al. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.06.010 · Cited by 33
The complement system: Biology, pathology, and therapeutic interventions
Li, X. X., & Woodruff, T. M. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100079 · Cited by 39
Current and Future Pharmacologic Complement Inhibitors
Risitano, A. M. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.01.009 · Cited by 32
The Importance of C4d in Biopsies of Kidney Transplant Recipients
Corrêa, R. R. M., Machado, J. R., da Silva, M. V., Helmo, F. R., Guimarães, C. S. D. O., Rocha, L. P., Faleiros, A. C. G., & dos Reis, M. A. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/678180 · Cited by 32
Lettiero, B., Andersen, A. J., Hunter, A. C., & Moghimi, S. M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.036 · Cited by 35
“The latter may include monoclonal antibodies against C5 [87] that cannot only block the release of anaphylatoxin C5a but also subsequent MAC formation, thus reducing related inflammatory and lytic processes, especially in the mild stage of AD.”
Multifocal Motor Neuropathy: Current Therapies and Novel Strategies
Nobile‐Orazio, E., & Gallia, F. (2013) · Drugs · doi:10.1007/s40265-013-0029-z · Cited by 32
“The monoclonal antibody eculizumab prevents cleavage of the human complement component 5 (C5) and thus inhibits terminal complement activation and membrane lysis via membrane attack complex [87].”
BackgroundParoxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape
Waheed, A., Shammo, J. M., & Dingli, D. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101158 · Cited by 36
Schubert, J. E. A., & Röth, A. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12520 · Cited by 36
“This is a crucial step for protection against infections and regulation of immune response (75, 76).”
BackgroundParoxysmal nocturnal hemoglobinuria: Where are we going
Kulasekararaj, A. G., & Λαζανά, Ι. (2023) · American Journal of Hematology · doi:10.1002/ajh.26882 · Cited by 42
Hughes, R. A. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.30 · Cited by 31
Taking Complement to the Clinic – has the Time Finally Come?
Lachmann, P. J., & Smith, R. A. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02258.x · Cited by 32
Complement and Complement Targeting Therapies in Glomerular Diseases
Andrighetto, S., Leventhal, J. S., Zaza, G., & Cravedi, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246336 · Cited by 34
“The drug use has been approved by European Medicines Agency’s (EMA) and FDA for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and aHUS [91].”
BackgroundMedusa's Head: The Complement System in Traumatic Brain and Spinal Cord Injury
Roselli, F., Karasu, E., Volpe, C., & Huber-Lang, M. S. (2017) · Journal of Neurotrauma · doi:10.1089/neu.2017.5168 · Cited by 32
Liu, F., Ryan, S. T., Fahnoe, K. C., Morgan, J. G., Cheung, A. E., Storek, M., Best, A., Chen, H. A., Locatelli, M., Xu, S., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.02.001 · Cited by 30
Malpica, L., van Duin, D., & Moll, S. (2019) · American Journal of Hematology · doi:10.1002/ajh.25642 · Cited by 34
“Eculizumab is a humanized monoclonal antibody that blocks the activation of terminal complement at C5 and, thus, prevents the formation of C5a and the terminal complement complex, C5b-9.”
BackgroundClinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis
Xiao, H. T., Wu, K., Liang, X., Li, R., & Lai, K. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.715036 · Cited by 29
“Additionally, this pathway is located downstream and avoids the impairment of C3b-mediated opsonization, immune protection, and immune regulation of immune complex clearance (35, 36).”
BackgroundSinger, A. L., Locke, J. E., Stewart, Z. A., Lonze, B. E., Hamilton, J. P., Scudiere, J. R., Anders, R. A., Rother, R. P., Brodsky, R. A., & Cameron, A. M. (2009) · Liver Transplantation · doi:10.1002/lt.21714 · Cited by 29
“Eculizumab is a humanized monoclonal antibody that inhibits the activation of the terminal complement at C5, thereby blocking both the generation of the anaphylotoxin C5a and the membrane attack complex C5b-9.(11) On the basis of the results of 2 multicenter phase III clinical trials, eculizumab was recently approved…”
BackgroundInfluentialZhou, H., Olsen, H. S., So, E. C., Mérigeon, E. Y., Rybin, D. V., Owens, J. M., LaRosa, G. J., Block, D. S., Strome, S. E., & Zhang, X. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016001917 · Cited by 29
Balancing efficacy and safety of complement inhibitors
Watanabe‐Kusunoki, K., & Anders, H. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103216 · Cited by 31
Eculizumab effect on the hemostatic state in patients with paroxysmal nocturnal hemoglobinuria
Seregina, E. A., Tsvetaeva, N. V., Nikulina, O. F., Zapariy, A. P., Erasov, A. V., Грибкова, И. В., Борисовна, О. Е., Ataullakhanov, F. I., & Balandina, A. N. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.11.021 · Cited by 29
Brachet, G., Bourquard, T., Gallay, N., Reiter, É., Gouilleux‐Gruart, V., Anne Poupon, B., & Watier, H. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.07.016 · Cited by 28
Jindal, S., Pedersen, D. V., Gera, N., Chandler, J., Patel, R., Neill, A., Cone, J., Zhang, Y., Yuan, C., Millman, E. E., et al. (2023) · Molecular Immunology · doi:10.1016/j.molimm.2023.12.004 · Cited by 29
Schrezenmeier, H., & Höchsmann, B. (2012) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2011.11.012 · Cited by 28
Role of complement and perspectives for intervention in transplantation
Chen, G., Chen, S., & Chen, X. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.09.002 · Cited by 29
Schmidt, C. Q., Harder, M. J., Nichols, E.-M., Hebecker, M., Anliker, M., Höchsmann, B., Simmet, T., Csincsi, Á. I., Uzonyi, B., Pappworth, I. Y., et al. (2016) · Immunobiology · doi:10.1016/j.imbio.2015.12.009 · Cited by 27
“Therapy with eculizumab (Soliris, Alexion Pharmaceuticals), a humanized monoclonal antibody directed against terminal complement component C5, inhibits MAC formation and thus intravascular lysis (Rother et al., 2007) (Supplemental Figure 1B).”
Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
Langman, C. B., & Palma, L. M. P. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s36249 · Cited by 27
“Such modifications should minimize the potential of eculizumab to induce pro-inflammatory responses.(7,8) Eculizumab was approved in 2011 in the United States(9) and shortly thereafter in Europe.”
BackgroundReview: The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases
Thurman, J. M., Frazer‐Abel, A. A., & Holers, V. M. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40219 · Cited by 27
“Practical experience in the area of infection risk mitigation has been gained through the clinical use of eculizumab and the means by which infection with Neisseria has been partially mitigated through longterm antibiotic treatment and/or close monitoring (27).”
InfluentialPedersen, H., Jensen, R. K., Hansen, A. G., Gadeberg, T. A. F., Thiel, S., Laursen, N. S., & Andersen, G. R. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.012339 · Cited by 28
Schmidt, C. Q., & Smith, R. J. (2022) · Immunological Reviews · doi:10.1111/imr.13164 · Cited by 32
Nishimura, J., Kawaguchi, T., Ito, S., Murai, H., Shimono, A., Matsuda, T., Fukamizu, Y., Akiyama, H., Hayashi, H., Nakano, T., et al. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03630-x · Cited by 30
Synthesis and characterization of 5,6,7,8-tetrahydroquinoline C5a receptor antagonists
Barbay, J. K., Gong, Y., Buntinx, M., Li, J., Claes, C., Hornby, P. J., Lommen, G. V., Wauwe, J. V., & He, W. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.03.049 · Cited by 27
Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis
Tokuyasu, D., Suzuki, S., Uzawa, A., Nagane, Y., Masuda, M., Konno, S., Kubota, T., Samukawa, M., Sugimoto, T., Ishizuchi, K., et al. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52051 · Cited by 26
“…is a humanized monoclonal antibody that binds specifically to human terminal complement protein C5 with high affinity, inhibiting enzymatic cleavage to protein C5a and C5b, and preventing C5a-induced che-motaxis of proinflammatory cells and formation of C5b-induced membrane attack complex 5,6 .”
Background
Metadata
- Authors
- Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L.
- Affiliations
- Alexion Pharmaceuticals (United States) (US)
- Johns Hopkins University (US)
- Corresponding author
- Rother, Russell P
- Venue
- Nature Biotechnology
- Published
- 2007-11
- Volume
- 25
- Issue
- 11
- Pages
- 1256-1264
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2004265876
- Cited by
- 778
- References
- 88
- Citations by year
- 2026: 34 · 2025: 38 · 2024: 43 · 2023: 58 · 2022: 34 · 2021: 47 · 2020: 59 · 2019: 49 · 2018: 42 · 2017: 52 · 2016: 60 · 2015: 39 · 2014: 41 · 2013: 38 · 2012: 43
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Update notices
- erratum (2007-12-01)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- eculizumab, paroxysmal nocturnal hemoglobinuria, complement inhibition, complement component C5, CD59, intravascular hemolysis, monoclonal antibodies, glycosylphosphatidylinositol deficiency, terminal complement activation, drug development
- MeSH terms
- Animals, Antibodies, Monoclonal, Clinical Trials as Topic, Complement C5, Drug Evaluation, Preclinical, Hemoglobinuria, Paroxysmal, Humans, Drug Design, Protein Engineering, Drug Approval, Complement Inactivating Agents, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.